Immunotherapy Biomarkers

Section Edited by Ignacio Melero, PhD

Consisting of predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies, clinical trial analyses and identification of novel immune biomarkers. Manuscripts will be prioritized for peer review and publication on the basis of innovation/novelty of the biomarker-oriented research, adequate validation, clinical relevance and technological novelty.

Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes

Barbara Manzanares-Martin, Arancha Cebrián Aranda, Laura del Puerto-Nevado, Rafael González, Sonia Solanes, Maria Auxiliadora Gómez-España, Jesús García-Foncillas, Enrique Aranda

10.1136/jitc-2020-001705

April 8, 2021

Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer

Myrto K Moutafi, Weiwei Tao, Richard Huang, James Haberberger, Brian Alexander, Shakti Ramkissoon, Jeffrey S Ross, Konstantinos Syrigos, Wei Wei, Lajos Pusztai, David L Rimm, Ioannis A Vathiotis

10.1136/jitc-2020-002230

April 8, 2021

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade

Romain Banchereau, Avantika S. Chitre, Alexis Scherl, Thomas D. Wu, Namrata S. Patil, Patricia de Almeida, Edward E. Kadel, III, Shravan Madireddi, Amelia Au-Yeung, Chikara Takahashi, Ying-Jiun Chen, Zora Modrusan, Jacqueline McBride, Rhea Nersesian, Ehab A. El-Gabry, Mark D. Robida, Jeffrey C. Hung, Marcin Kowanetz, Wei Zou, Mark McCleland, Patrick Caplazi, Shadi Toghi Eshgi, Hartmut Koeppen, Priti S. Hegde, Ira Mellman, W. Rodney Mathews, Thomas Powles, Sanjeev Mariathasan, Jane Grogan, William E O'Gorman

10.1136/jitc-2020-002231

April 7, 2021

Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants

Alessandra Dondero, Martina Morini, Davide Cangelosi, Katia Mazzocco, Martina Serra, Grazia Maria Spaggiari, Gianluca Rotta, Annalisa Tondo, Franco Locatelli, Aurora Castellano, Francesca Scuderi, Angela Rita Sementa, Alessandra Eva, Massimo Conte, Alberto Garaventa, Cristina Bottino, Roberta Castriconi

10.1136/jitc-2020-002293

April 1, 2021

Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer

Qiaoqi Sui, Dingxin Liu, Wu Jiang, Jinghua Tang, Lingheng Kong, Kai Han, Leen Liao, Yuan Li, Qingjian Ou, Binyi Xiao, Guochen Liu, Yihong Ling, Jiewei Chen, Zexian Liu, Zhixiang Zuo, Zhizhong Pan, Penghui Zhou, Jian Zheng, Pei-Rong Ding

10.1136/jitc-2020-001498

March 29, 2021

Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)

Biagio Ricciuti, Greg Jones, Mariano Severgnini, Joao V Alessi, Gonzalo Recondo, Marissa Lawrence, Tim Forshew, Christine Lydon, Mizuki Nishino, Michael Cheng, Mark Awad

10.1136/jitc-2020-001504

March 25, 2021

High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer

Yacine Bareche, Sandra Pommey, Mayra Carneiro, Laurence Buisseret, Isabelle Cousineau, Pamela Thebault, Pavel Chrobak, Laudine Communal, David Allard, Simon C Robson, Anne-Marie Mes-Masson, Diane Provencher, Rejean Lapointe, John Stagg

10.1136/jitc-2020-001965

March 25, 2021

Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients

Angelika M Starzer, Anna S Berghoff, Rainer Hamacher, Erwin Tomasich, Katharina Feldmann, Teresa Hatziioannou, Stefan Traint, Wolfgang Lamm, Iris M Noebauer-Huhmann, Julia Furtner, Leonhard Müllauer, Gabriele Amann, Sebastian Bauer, Hans-Ulrich Schildhaus, Matthias Preusser, Gerwin Heller, Thomas Brodowicz

10.1136/jitc-2020-001458

March 24, 2021

Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer

Colt Egelston, Weihua Guo, Susan Yost, Jin Sun Lee, David Rose, Christian Avalos, Jian Ye, Paul Frankel, Daniel Schmolze, James Waisman, Peter Lee, Yuan Yuan

10.1136/jitc-2020-002084

March 23, 2021

Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score

Gino M Dettorre, Saoirse Dolly, Angela Loizidou, John Chester, Amanda Jackson, Uma Mukherjee, Alberto Zambelli, Juan Aguilar-Company, Mark Bower, Christopher C T Sng, Ramon Salazar, Alexia Bertuzzi, Joan Brunet, Ricard Mesia, Ailsa Sita-Lumsden, Elia Seguí, Federica Biello, Daniele Generali, Salvatore Grisanti, Pavetha Seeva, Gianpiero Rizzo, Michela Libertini, Antonio Maconi, Charlotte Moss, Beth Russell, Nadia Harbeck, Bruno Vincenzi, Rossella Bertulli, Diego Ottaviani, Raquel Liñan, Andrea Marrari, M Carmen Carmona-García, Neha Chopra, Carlo Alberto Tondini, Oriol Mirallas, Valeria Tovazzi, Vittoria Fotia, Claudia Andrea Cruz, Nadia Saoudi-Gonzalez, Eudald Felip, Ariadna Roqué, Alvin J X Lee, Tom Newsom-Davis, David García-Illescas, Roxana Reyes, Yien Ning Sophia Wong, Daniela Ferrante, Lorenza Scotti, Javier Marco-Hernández, Isabel Ruiz-Camps, Andrea Patriarca, Lorenza Rimassa, Lorenzo Chiudinelli, Michela Franchi, Armando Santoro, Aleix Prat, Alessandra Gennari, Mieke Van Hemelrijck, Josep Tabernero, Nikolaos Diamantis, David J Pinato

10.1136/jitc-2020-002277

March 22, 2021